公开(公告)号：US20180355064A1

公开(公告)日：2018-12-13

申请号：US15984822

申请日：2018-05-21

申请人： GLENMARK PHARMACEUTICALS S.A.

发明人： Stanislas BLEIN ,  Romain OLLIER ,  Darko SKEGRO ,  Samuel HOU

IPC分类号： C07K16/46 ,  C07K16/28 ,  C07K16/42 ,  C07K16/32

CPC分类号： C07K16/468 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4291 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.

公开(公告)号：US20200079863A1

公开(公告)日：2020-03-12

申请号：US16437550

申请日：2019-06-11

申请人： Glenmark Pharmaceuticals S.A.

发明人： Antoine ATTINGER ,  Jonathan Albert BACK ,  Stanislas BLEIN ,  Rami LISSILAA ,  Darko SKEGRO

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61K39/395

摘要： The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.

公开(公告)号：US20200024367A1

公开(公告)日：2020-01-23

申请号：US16288980

申请日：2019-02-28

申请人： Glenmark Pharmaceuticals S.A.

发明人： Stanislas BLEIN ,  Darko SKEGRO ,  Paul WASSMANN

IPC分类号： C07K16/46 ,  C07K16/28 ,  C07K16/32 ,  C07K16/18

摘要： The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.

公开(公告)号：US20190135918A1

公开(公告)日：2019-05-09

申请号：US16159231

申请日：2018-10-12

申请人： GLENMARK PHARMACEUTICALS S.A.

发明人： Romain OLLIER ,  Samuel HOU ,  Rami LISSILAA ,  Darko SKEGRO ,  Jonathan BACK

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.

公开(公告)号：US20160319027A1

公开(公告)日：2016-11-03

申请号：US15092265

申请日：2016-04-06

申请人： GLENMARK PHARMACEUTICALS S.A.

发明人： Stanislas BLEIN ,  Romain OLLIER ,  Darko SKEGRO ,  Adrian WALMSLEY ,  Harald MOTTL

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K9/00 ,  A61K39/395

CPC分类号： C07K16/2863 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/22 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates generally to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies. In one aspect, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties for use in methods of treating neuroma and/or bone associated pain.